Additional Relevant Details Under the terms of the agreement, Enterome is eligible to receive an upfront payment plus R&D funding from Janssen. Janssen receives an option to take an exclusive license to further develop and commercialize promising candidates that may arise from the collaboration. The Janssen Human Microbiome Institute will also join the collaboration to help accelerate the translation of microbiome science into therapeutic solutions in the area of Crohn’s disease. The collaboration is based on initial findings by INRA showing that some commensal (symbiotic) bacteria elicit anti-inflammatory effects in the human gut.